Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dissolution testing of a poorly soluble compound using the flow-through cell dissolution apparatus.

Shobha N Bhattachar1, James A Wesley, Ann Fioritto

  • 1Pfizer Global R&D, 2800 Plymouth Road, Ann Arbor, MI 48105, USA. shobha.bhattachar@pfizer.com

International Journal of Pharmaceutics
|March 14, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.

Molecular metabolism·2025
Same author

Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial.

Diabetes, obesity & metabolism·2025
Same author

Effect of Gastric pH on the Pharmacokinetics of Atorvastatin and its Metabolites in Healthy Participants.

European journal of drug metabolism and pharmacokinetics·2025
Same author

Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2024
Same author

Seizing the opportunity of the moment; nurse education in Cameroon: a grounded theory research study.

Journal of research in nursing : JRN·2022
Same author

Modulating target engagement of small molecules via drug delivery: approaches and applications in drug discovery and development.

Drug discovery today·2020

Investigating Pfizer Compound PD198306 dissolution revealed suspension loading enhances drug release. Optimal flow rate ensures reliable particle size discrimination for poorly soluble compounds.

Area of Science:

  • Pharmaceutical Sciences
  • Drug Delivery
  • Physical Chemistry

Background:

  • Poorly soluble compounds present challenges in drug formulation and bioavailability.
  • Pfizer Compound PD198306 exhibits poor wettability, impacting its dissolution characteristics.
  • Optimizing dissolution methods is critical for developing effective drug products.

Purpose of the Study:

  • To investigate the dissolution behavior of Pfizer Compound PD198306.
  • To evaluate the impact of powder loading methods and flow rate on dissolution.
  • To identify optimal conditions for achieving maximum dissolution rate and extent.

Main Methods:

  • Utilized a flow-through cell dissolution apparatus with a pH 9 sodium phosphate buffer containing 0.5% sodium lauryl sulfate (SLS).

Related Experiment Videos

  • Tested both unmicronized and micronized drug powders.
  • Compared various powder loading techniques and dissolution medium flow rates (specifically 4 ml/min).

    • Main Results:

    • Pfizer Compound PD198306 demonstrated poor wettability, even with 0.5% SLS.
    • Loading the drug as a suspension into the dissolution cells yielded the most favorable dissolution profile.
    • A flow rate of 4 ml/min proved effective for particle size discrimination.

    Conclusions:

    • Suspension loading is the preferred method for enhancing the dissolution of poorly soluble compounds like PD198306.
    • The flow rate significantly influences dissolution and particle size assessment.
    • These findings provide valuable insights for the formulation development of poorly soluble drugs.